Oslo, Norway, 8 March 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 28 September 2023 regarding the approval of a registration document (the “Registration Document”) which was prepared to be used as a base prospectus for the purpose of listing new shares in the Company related to the convertible bond facility with Atlas Special Opportunities LLC (“Atlas”).
Further reference is made to the stock exchange announcements published by the Company on 4 and 5 March 2024, announcing that Atlas had by notice of conversion, requested conversion of convertible bonds into a total of 171,154 new shares in the Company. A total of 99,548 of the new shares (the “New Shares”) were issued at a separate ISIN pending publication of a prospectus.
The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today approved a securities note, a supplement to the Registration Document and a summary (together with the Registration Document, referred to as the “Prospectus”) prepared for the listing of the New Shares.
The Prospectus is available at the Company’s website https://www.circio.com/en/section/investors/prospectus/.
***
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.